A new study published in Haematologica by CCA researcher Bauke Ylstra and colleagues sheds new light on the risk of a rare but deadly cancer in people with celiac disease.
The researchers show that cancer‑related genetic mutations found in routine diagnostic small‑intestinal biopsies do not reliably predict who will go on to develop enteropathy‑associated T‑cell lymphoma (EATL). These mutations appear just as often in patients who never develop lymphoma as in those who do, meaning that current biopsy‑based genetic testing can give both false alarms and false reassurance.
A rare but highly aggressive complication
The study focuses on why some people with celiac disease go on to develop EATL, a very rare but highly aggressive and often fatal form of cancer. People with celiac disease must follow a strict lifelong gluten‑free dietas the only effective medical treatment to heal the intestine and prevent further harm. Even then, some patients are at risk of serious complications like refractory celiac disease (intestinal inflammation despite a strict diet), and EATL the most feared of them. Until now, doctors thought that finding cancer‑related genetic changes in biopsies of patients with refractory celiac disease could help predict which patients are most likely to develop this lymphoma.
Putting an existing assumption to the test
This study puts that assumption to the test. They examined small‑intestinal tissue from people with refractory celiac disease and from people with EATL. Using the latest sequencing techniques, they searched for T-cell rearrangements, mutations and structural variation, to decipher the oncogenetic of path of EATL development.
The main finding is both surprising and important: similar genetic changes were found in patient samples who later did develop EATL and in samples of patients who did not. In other words, the presence of these mutations or structural variation in a biopsy does not automatically mean that someone is at risk to develop this cancer. Conversely, if no mutations are found in the sampled tissue, that does not guarantee that dangerous cells will not develop elsewhere in the intestine.
Biopsy results should not guide treatment alone
The message for clinical practice is clear: genetic abnormalities in refractory celiac disease biopsies, even in well‑known cancer pathways like JAK/STAT, should not be used on their own to estimate a patient’s cancer risk or to justify very intensive treatments. Doing so could lead to unnecessarily aggressive therapy in people who may never develop EATL, and to false reassurance in people whose dangerous cells could still develop or were simply not captured in the biopsy.
Better tests are needed
An urgent need for better ways to assess EATL risk in people with celiac disease is required. This may include new blood tests, more refined analyses of immune cells, or other types of biomarkers that more reliably identify patients at truly high risk. Only with such improved tools can doctors confidently offer strong, potentially burdensome treatments to those who genuinely need them, while sparing others from therapies that bring substantial side effects but little real benefit.